Cargando…

The clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: Two decades of follow-up from the Tehran Lipid and Glucose Study

BACKGROUND: To evaluate the impact of different definitions of metabolic syndrome (MetS) and their components on the risk of sudden cardiac death (SCD) among the Iranian population according to the World Health Organization (WHO), International Diabetes Federation (IDF), Adult Treatment Panel III (A...

Descripción completa

Detalles Bibliográficos
Autores principales: Masrouri, Soroush, Moazzeni, Seyyed Saeed, Cheraghloo, Neda, Azizi, Fereidoun, Hadaegh, Farzad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719125/
https://www.ncbi.nlm.nih.gov/pubmed/36463175
http://dx.doi.org/10.1186/s12933-022-01707-1
_version_ 1784843248710189056
author Masrouri, Soroush
Moazzeni, Seyyed Saeed
Cheraghloo, Neda
Azizi, Fereidoun
Hadaegh, Farzad
author_facet Masrouri, Soroush
Moazzeni, Seyyed Saeed
Cheraghloo, Neda
Azizi, Fereidoun
Hadaegh, Farzad
author_sort Masrouri, Soroush
collection PubMed
description BACKGROUND: To evaluate the impact of different definitions of metabolic syndrome (MetS) and their components on the risk of sudden cardiac death (SCD) among the Iranian population according to the World Health Organization (WHO), International Diabetes Federation (IDF), Adult Treatment Panel III (ATP III), and Joint Interim Statement (JIS) criteria. METHODS: The study population included a total of 5,079 participants (2,785 women) aged ≥ 40 years, free of cardiovascular disease (CVD) at baseline. Participants were followed for incident SCD annually up to 20 March 2018. Multivariable Cox proportional hazards regression models were applied to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) of MetS and its components for incident SCD. RESULTS: The prevalence of MetS ranged from 27.16% to 50.81%, depending on the criteria used. Over a median of 17.9 years of follow-up, 182 SCD events occurred. The WHO, IDF, and JIS definitions were strong predictors of SCD with multivariable-adjusted HRs (95% CI) of 1.68 (1.20–2.35), 1.51 (1.12–2.03), and 1.47 (1.08–1.98), respectively; these associations significantly attenuated after further adjustment for MetS components. MetS by the ATP III definition was not associated with the risk of SCD after controlling for antihypertensive, glucose-lowering, and lipid-lowering medication use. Among the components of MetS, high blood pressure (WHO definition), high waist circumference (using the national cutoff of ≥ 95 cm), and high glucose component by the JIS/IDF definitions remained independent predictors of SCD with HRs of 1.79 (1.29–2.48), 1.46 (1.07–2.00), and 1.52 (1.12–2.05), respectively. CONCLUSIONS: The constellation of MetS, except for when defined with ATP III definition, is a marker for identifying individuals at higher risk for SCD; however, not independent of its components. Among MetS components, abdominal obesity using the population-specific cutoff point, high glucose component (JIS/IDF definitions), and high blood pressure (WHO definition) were independent predictors of SCD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-022-01707-1.
format Online
Article
Text
id pubmed-9719125
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97191252022-12-04 The clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: Two decades of follow-up from the Tehran Lipid and Glucose Study Masrouri, Soroush Moazzeni, Seyyed Saeed Cheraghloo, Neda Azizi, Fereidoun Hadaegh, Farzad Cardiovasc Diabetol Research BACKGROUND: To evaluate the impact of different definitions of metabolic syndrome (MetS) and their components on the risk of sudden cardiac death (SCD) among the Iranian population according to the World Health Organization (WHO), International Diabetes Federation (IDF), Adult Treatment Panel III (ATP III), and Joint Interim Statement (JIS) criteria. METHODS: The study population included a total of 5,079 participants (2,785 women) aged ≥ 40 years, free of cardiovascular disease (CVD) at baseline. Participants were followed for incident SCD annually up to 20 March 2018. Multivariable Cox proportional hazards regression models were applied to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) of MetS and its components for incident SCD. RESULTS: The prevalence of MetS ranged from 27.16% to 50.81%, depending on the criteria used. Over a median of 17.9 years of follow-up, 182 SCD events occurred. The WHO, IDF, and JIS definitions were strong predictors of SCD with multivariable-adjusted HRs (95% CI) of 1.68 (1.20–2.35), 1.51 (1.12–2.03), and 1.47 (1.08–1.98), respectively; these associations significantly attenuated after further adjustment for MetS components. MetS by the ATP III definition was not associated with the risk of SCD after controlling for antihypertensive, glucose-lowering, and lipid-lowering medication use. Among the components of MetS, high blood pressure (WHO definition), high waist circumference (using the national cutoff of ≥ 95 cm), and high glucose component by the JIS/IDF definitions remained independent predictors of SCD with HRs of 1.79 (1.29–2.48), 1.46 (1.07–2.00), and 1.52 (1.12–2.05), respectively. CONCLUSIONS: The constellation of MetS, except for when defined with ATP III definition, is a marker for identifying individuals at higher risk for SCD; however, not independent of its components. Among MetS components, abdominal obesity using the population-specific cutoff point, high glucose component (JIS/IDF definitions), and high blood pressure (WHO definition) were independent predictors of SCD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-022-01707-1. BioMed Central 2022-12-03 /pmc/articles/PMC9719125/ /pubmed/36463175 http://dx.doi.org/10.1186/s12933-022-01707-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Masrouri, Soroush
Moazzeni, Seyyed Saeed
Cheraghloo, Neda
Azizi, Fereidoun
Hadaegh, Farzad
The clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: Two decades of follow-up from the Tehran Lipid and Glucose Study
title The clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: Two decades of follow-up from the Tehran Lipid and Glucose Study
title_full The clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: Two decades of follow-up from the Tehran Lipid and Glucose Study
title_fullStr The clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: Two decades of follow-up from the Tehran Lipid and Glucose Study
title_full_unstemmed The clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: Two decades of follow-up from the Tehran Lipid and Glucose Study
title_short The clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: Two decades of follow-up from the Tehran Lipid and Glucose Study
title_sort clinical value of metabolic syndrome and its components with respect to sudden cardiac death using different definitions: two decades of follow-up from the tehran lipid and glucose study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719125/
https://www.ncbi.nlm.nih.gov/pubmed/36463175
http://dx.doi.org/10.1186/s12933-022-01707-1
work_keys_str_mv AT masrourisoroush theclinicalvalueofmetabolicsyndromeanditscomponentswithrespecttosuddencardiacdeathusingdifferentdefinitionstwodecadesoffollowupfromthetehranlipidandglucosestudy
AT moazzeniseyyedsaeed theclinicalvalueofmetabolicsyndromeanditscomponentswithrespecttosuddencardiacdeathusingdifferentdefinitionstwodecadesoffollowupfromthetehranlipidandglucosestudy
AT cheraghlooneda theclinicalvalueofmetabolicsyndromeanditscomponentswithrespecttosuddencardiacdeathusingdifferentdefinitionstwodecadesoffollowupfromthetehranlipidandglucosestudy
AT azizifereidoun theclinicalvalueofmetabolicsyndromeanditscomponentswithrespecttosuddencardiacdeathusingdifferentdefinitionstwodecadesoffollowupfromthetehranlipidandglucosestudy
AT hadaeghfarzad theclinicalvalueofmetabolicsyndromeanditscomponentswithrespecttosuddencardiacdeathusingdifferentdefinitionstwodecadesoffollowupfromthetehranlipidandglucosestudy
AT masrourisoroush clinicalvalueofmetabolicsyndromeanditscomponentswithrespecttosuddencardiacdeathusingdifferentdefinitionstwodecadesoffollowupfromthetehranlipidandglucosestudy
AT moazzeniseyyedsaeed clinicalvalueofmetabolicsyndromeanditscomponentswithrespecttosuddencardiacdeathusingdifferentdefinitionstwodecadesoffollowupfromthetehranlipidandglucosestudy
AT cheraghlooneda clinicalvalueofmetabolicsyndromeanditscomponentswithrespecttosuddencardiacdeathusingdifferentdefinitionstwodecadesoffollowupfromthetehranlipidandglucosestudy
AT azizifereidoun clinicalvalueofmetabolicsyndromeanditscomponentswithrespecttosuddencardiacdeathusingdifferentdefinitionstwodecadesoffollowupfromthetehranlipidandglucosestudy
AT hadaeghfarzad clinicalvalueofmetabolicsyndromeanditscomponentswithrespecttosuddencardiacdeathusingdifferentdefinitionstwodecadesoffollowupfromthetehranlipidandglucosestudy